Document is current
Any future updates will be listed below
-
Authors
Sierro-Martínez, Belén
Escamilla-Gómez, Virginia
Pérez-Ortega, Laura
Guijarro-Albaladejo, Beatriz
Hernández-Díaz, Paola
de la Rosa-Garrido, María
Lara-Chica, Maribel
Rodríguez-Gil, Alfonso
Reguera-Ortega, Juan Luis
Sanoja-Flores, Luzalba
Arribas-Arribas, Blanca
Montiel-Aguilera, Miguel Ángel
Carmona, Gloria
Robles, Maria Jose
Caballero-Velázquez, Teresa
Briones, Javier
Einsele, Hermann
Hudecek, Michael
Pérez-Simón, Jose Antonio https://orcid.org/0000-0003-3616-6101
García-Guerrero, Estefanía https://orcid.org/0000-0002-3041-9860
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PFIS-FI21/00222, CD21/00162, CP23/00139)
Consejeria de Salud y Familias, Junta de Andalucia (RH*-0042-2020)
Consejeria de Universidad, Investigacion e Innovacion, Junta de Andalucia (DOC_01652)
- License Information
-
More Information
Article History
Accepted: 9 August 2024
First Online: 27 August 2024
Declarations
:
: Peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy donors kindly donated by the Regional Centre for Blood Transfusions at Virgen del Rocío University Hospital, Sevilla (Spain) after written informed consent. Leukapheresis from healthy donors were obtained from the leukapheresis unit of the Virgen del Rocío University Hospital, Sevilla (Spain) after written informed consent. Bone-marrow samples from patients with multiple myeloma were obtained from HUVR-IBiS Biobank at Hospital Virgen del Rocío after written informed consent. The University of Würzburg Institutional Animal Care and Use Committee and the Institutional Animal Care and Use Committee at Institute of Biomedicine in Seville approved all animal procedures.
: All authors consent for publication.
: JAPS is an advisor or consultant for Novartis, Janssen, Roche, Jazz Pharmaceuticals, Amgen, and Gilead Sciences; reports research support from Novartis, Janssen, Pfizer, Roche, and Takeda; reports travel support from Roche, Gilead Sciences and Janssen; and reports patents, royalties, or other intellectual property from Entourage Bioscience on cannabinoid derivatives. EGG has been a consultant to Cellgene and GLS, and received travel grants and/or speaker fees from Cellgene, Amgen, Janssen. EGG and MH are co-inventors on a patent application on the use of BCMA-CAR T-cell therapy in combination with ATRA, “Combination treatment of BCMA CAR-T and ATRA in multiple myeloma” (WO2021/209498 A1), that has been filed by the University of Würzburg, Würzburg, Germany and licensed to T-CURX GmbH, Würzburg, Germany.
